Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
2015; Ferrata Storti Foundation; Volume: 100; Issue: 10 Linguagem: Inglês
10.3324/haematol.2014.117077
ISSN1592-8721
AutoresMeletios Α. Dimopoulos, K. Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, L. Garderet, Michèle Cavo, V. L. Ivanova, Adrián Alegre, Joaquín Martínez‐López, Christopher Chen, Andrew Spencer, Stefan Knop, Nizar J. Bahlis, Christoph Renner, Xin Yu, Kevin Hong, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel,
Tópico(s)Cancer Treatment and Pharmacology
ResumoPatients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P
Referência(s)